Abraxis BioScience files $400 million stock, preferreds, debt shelf

By Devika Patel

Knoxville, Tenn., June 18 - Abraxis BioScience, Inc. filed a $400 million shelf registration in an S-3 filing with the Securities and Exchange Commission.

The registration covers debt securities, common stock, preferred stock, rights, units and warrants, along with 2 million shares to be sold by stockholders.

The securities may be structured as convertibles.

Proceeds will be used for general corporate purposes.

Abraxis is a Los Angeles-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.